Abstract
Levonorgestrel (1.5 mg) is commonly used for emergency contraception to prevent an unwanted pregnancy after an unprotected intercourse. We found that postovulatory administration of 1.5 mg of levonorgestrel to women with a subsequent or existing early pregnancy did not affect the immunohistochemical expressions of estrogen receptors (ER(alpha), ER(beta)), P receptors (PR(B), PR(A+B)), androgen receptor (AR), or proliferation index Ki67 in the first-trimester decidua and chorionic villi.
Publication types
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Cell Proliferation
-
Chorionic Villi / metabolism*
-
Contraception, Postcoital / methods*
-
Contraceptive Agents, Female / pharmacology
-
Decidua / cytology
-
Decidua / metabolism*
-
Estrogen Receptor alpha / drug effects
-
Estrogen Receptor alpha / metabolism
-
Estrogen Receptor beta / drug effects
-
Estrogen Receptor beta / metabolism
-
Female
-
Humans
-
Ki-67 Antigen / drug effects
-
Ki-67 Antigen / metabolism*
-
Levonorgestrel / pharmacology*
-
Pregnancy
-
Pregnancy Trimester, First / metabolism
-
Receptors, Androgen / drug effects
-
Receptors, Androgen / metabolism*
-
Receptors, Estrogen / drug effects
-
Receptors, Estrogen / metabolism*
-
Receptors, Progesterone / drug effects
-
Receptors, Progesterone / metabolism*
Substances
-
Contraceptive Agents, Female
-
Estrogen Receptor alpha
-
Estrogen Receptor beta
-
Ki-67 Antigen
-
Receptors, Androgen
-
Receptors, Estrogen
-
Receptors, Progesterone
-
progesterone receptor A
-
progesterone receptor B
-
Levonorgestrel